middle.news
Actinogen Accelerates Alzheimer's Trial with $22.9M Cash Boost
7:03pm on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Actinogen Accelerates Alzheimer's Trial with $22.9M Cash Boost
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
XanaMIA phase 2b/3 trial enrolling 220 biomarker-positive Alzheimer's patients
First US patient randomized; recruitment intensifying post-holidays
Interim analysis expected in Q4 2025; final results anticipated H2 2026
Cash balance strengthened to $22.9 million, funded to mid-late 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE